title: Serum antiphospholipid antibody levels in pseudoexfoliation.
abstract: OBJECTIVE
  To evaluate the levels of serum antiphospholipid antibodies in patients with pseudoexfoliation syndrome (PXS), pseudoexfoliation glaucoma (PXG), primary open-angle glaucoma, and healthy controls.
  
  
  METHODS
  This prospective study included 17 patients with PXS, 19 patients with pseudoexfoliation glaucoma, 15 patients with primary open-angle glaucoma, and 19 normal individuals. Venous blood samples were obtained in the morning after an overnight 8-hour fasting. Anticardiolipin antibodies, isotypes IgG and IgM were measured by means of an enzyme-linked immunosorbent assay. Lupus anticoagulant antibodies were measured by dilute Russell viper venom time screen test.
  
  
  RESULTS
  Mean±standard mean of error of anticardiolipin antibody IgG levels in patients with PXS and PEG were significantly higher than those of the controls (P<0.05). The mean lupus anticoagulant antibody levels of the controls were not statistically different from the levels of patients with PXS, pseudoexfoliation glaucoma, and primary open-angle glaucoma (P>0.05). The anticardiolipin antibody IgG concentrations above the cutoff value of 15 GPL/mL were found in 8 patients (21.05%) with pseudoexfoliation. There was no individual in the control group having anticardiolipin antibody IgG level above the cutoff value (P<0.05).
  
  
  CONCLUSIONS
  Elevated serum antiphospholipid antibodies, a risk factor for cardiovascular and cerebrovascular disease, is more common in patients with PXS and pseudoexfoliation glaucoma than in the healthy controls and in patients with primary open-angle glaucoma.
authors.affiliation: Department of Ophthalmology, Kocaeli University Medical School, Kocaeli, Turkey. ozgulaltintas@yahoo.com
authors.forename: Ozgul
authors.initials: O
authors.lastname: Altintas
authors.forename: Nursen
authors.initials: N
authors.lastname: Yuksel
authors.forename: Gulden Tamer
authors.initials: GT
authors.lastname: Sonmez
authors.forename: Berna
authors.initials: B
authors.lastname: Ozkan
authors.forename: Levent
authors.initials: L
authors.lastname: Altintas
authors.forename: Şeyda
authors.initials: Ş
authors.lastname: Caliskan
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Caglar
mesh_terms: D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D017889:Exfoliation Syndrome / Q000276:immunology*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007132:Immunoglobulin Isotypes; D007075:Immunoglobulin M / Q000097:blood; D007429:Intraocular Pressure; D016682:Lupus Coagulation Inhibitor / Q000097:blood*; D008297:Male; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D017153:Antibodies, Anticardiolipin; D007074:Immunoglobulin G; D007132:Immunoglobulin Isotypes; D007075:Immunoglobulin M; D016682:Lupus Coagulation Inhibitor